Executive Wealth Management LLC boosted its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 100.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 100 shares of the medical equipment provider’s stock after purchasing an additional 50 shares during the quarter. Executive Wealth Management LLC’s holdings in ABIOMED were worth $26,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of ABIOMED by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 606,848 shares of the medical equipment provider’s stock worth $196,924,000 after buying an additional 32,418 shares during the last quarter. IFM Investors Pty Ltd boosted its holdings in shares of ABIOMED by 6.8% in the 1st quarter. IFM Investors Pty Ltd now owns 2,655 shares of the medical equipment provider’s stock worth $758,000 after buying an additional 170 shares during the last quarter. Brookstone Capital Management boosted its holdings in shares of ABIOMED by 25.8% in the 1st quarter. Brookstone Capital Management now owns 1,040 shares of the medical equipment provider’s stock worth $297,000 after buying an additional 213 shares during the last quarter. Central Bank & Trust Co. boosted its holdings in shares of ABIOMED by 326.6% in the 1st quarter. Central Bank & Trust Co. now owns 1,011 shares of the medical equipment provider’s stock worth $289,000 after buying an additional 774 shares during the last quarter. Finally, Deltec Asset Management LLC purchased a new position in shares of ABIOMED in the 1st quarter worth about $810,000. 86.63% of the stock is currently owned by institutional investors.
In related news, COO David M. Weber sold 8,095 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $206.26, for a total value of $1,669,674.70. Following the sale, the chief operating officer now directly owns 132,913 shares in the company, valued at approximately $27,414,635.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.40% of the company’s stock.
Shares of ABIOMED stock opened at $192.06 on Friday. ABIOMED, Inc. has a 52-week low of $181.02 and a 52-week high of $459.75. The stock’s 50-day simple moving average is $243.34 and its 200 day simple moving average is $281.15. The stock has a market capitalization of $8.95 billion, a P/E ratio of 51.21, a P/E/G ratio of 1.74 and a beta of 0.31.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.01. ABIOMED had a return on equity of 19.84% and a net margin of 32.35%. The business had revenue of $207.70 million for the quarter, compared to analysts’ expectations of $210.96 million. During the same period in the previous year, the business posted $1.95 EPS. The firm’s quarterly revenue was up 15.4% compared to the same quarter last year. Research analysts predict that ABIOMED, Inc. will post 4.3 earnings per share for the current fiscal year.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Read More: What are catch-up contributions?
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.